EUCTR2011-001424-38-BE进行中（未招募）1 期
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study toEvaluate the Efficacy and Safety of SAR236553/REGN727 over 24 weeks in Patients with Hypercholesterolemia
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 182
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with hypercholesterolemia
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 162
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Age < 18 or legal age of adulthood, whichever is greater
- •LDL-C < 100 mg/dL (< 2.59 mmol/L) or > 190 mg/dL (> 4.9 mmol/L)
- •Fasting serum TG > 400 mg/dL (> 4.52 mmol/L)
- •Known history of homozygous or heterozygous familial hypercholesterolemia
研究者
相似试验
已完成
3 期
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 over 24 weeks in Patients with Hypercholesterolemiahypercholesterolemiahypercholesterolemiehigh cholesterolNL-OMON36881Sanofi-aventis30
进行中（未招募）
不适用
A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Renal ImpairmentEUCTR2010-019777-15-DEGlaxoSmithKline LLC500
进行中（未招募）
不适用
Efficacy and Safety of SAR236553 (REGN727) Versus Ezetimibe in Patients with HypercholesterolemiaEUCTR2011-001424-38-NLsanofi-aventis Recherche & Développement182
进行中（未招募）
不适用
Efficacy and Safety of SAR236553 (REGN727) Versus Ezetimibe in Patients with HypercholesterolemiaEUCTR2011-001424-38-FIsanofi-aventis Recherche & Développement182
进行中（未招募）
不适用
A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Noninferiority, Multicenter Study of Ceftobiprole Medocaril Versus Cefepime With or Without Vancomycin in the Treatment of Subjects With Fever and NeutropeniaSubjects 18 years of age or older with fever and neutropenia after chemotherapy for cancer, who require i.v. therapy for treatment of fever and neutropeniaEUCTR2007-003464-22-BEJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium340